Scarica l'app Stockscreener
19.90
0.66%
0.13
Dopo l'orario di chiusura:
19.70
-0.20
-1.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.77
Aprire:
$19.55
Volume 24 ore:
909.51K
Relative Volume:
0.86
Capitalizzazione di mercato:
$1.02B
Reddito:
$75.04M
Utile/perdita netta:
$-167.18M
Rapporto P/E:
-6.2252
EPS:
-3.1967
Flusso di cassa netto:
$-168.39M
1 W Prestazione:
+5.01%
1M Prestazione:
+23.91%
6M Prestazione:
+69.36%
1 anno Prestazione:
+79.44%
Intervallo 1D:
$19.27
$20.11
Intervallo di 1 settimana:
$18.24
$21.30
Portata 52W:
$9.235
$21.30
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Nome
Kalvista Pharmaceuticals Inc
Settore
Industria
Telefono
(857) 999-0075
Indirizzo
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Compare KALV vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
19.90 | 1.02B | 75.04M | -167.18M | -168.39M | -3.1967 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Reiterato | Needham | Buy |
| 2026-01-06 | Reiterato | Needham | Buy |
| 2025-01-31 | Iniziato | JMP Securities | Mkt Outperform |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-12-18 | Iniziato | BofA Securities | Buy |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-29 | Iniziato | SVB Leerink | Outperform |
| 2019-03-20 | Iniziato | Needham | Buy |
| 2018-10-30 | Iniziato | Jefferies | Buy |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Iniziato | BTIG Research | Buy |
Mostra tutto
Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie
Big Picture: Will KalVista Pharmaceuticals Inc face regulatory challengesMarket Performance Recap & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Wall Street Zen Downgrades KalVista Pharmaceuticals (NASDAQ:KALV) to Hold - marketbeat.com
Why KalVista Pharmaceuticals (KALV) Is Up 5.0% After Promising Pediatric EKTERLY HAE Trial Results – And What's Next - Sahm
A Look At KalVista Pharmaceuticals (KALV) Valuation After Positive KONFIDENT KID EKTERLY Trial Update - Sahm
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Hits New 1-Year HighShould You Buy? - MarketBeat
KALV Should I Buy - intellectia.ai
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE Trial - Yahoo Finance
KalVista Pharmaceuticals Stock: Positive Pediatric Trial Data Positions KALV for HAE Market Expansio - AD HOC NEWS
Hennion & Walsh Asset Management Inc. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALV - marketbeat.com
KalVista reports interim data on pediatric HAE treatment trial By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference - BioSpace
(KALV) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
KalVista (KALV) Announces Positive Interim Results from KONFIDEN - GuruFocus
KalVista Announces Positive Interim Data for Pediatric HAE Treatment - National Today
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data - The National Law Review
KalVista reports interim data on pediatric HAE treatment trial - Investing.com
HC Wainwright Has Negative Forecast for KALV FY2028 Earnings - marketbeat.com
KalVista Pharmaceuticals Inc Stock Historical Valuations | HAM:4XC1 - GuruFocus
Stifel Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Sells 174,645 Shares of Stock - marketbeat.com
KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Sells 39,986 Shares of Stock - marketbeat.com
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded to Buy at Wall Street Zen - marketbeat.com
Venrock healthcare sells KalVista (KALV) shares for $3.69 million - Investing.com UK
Venrock healthcare sells KalVista (KALV) shares for $3.69 million By Investing.com - Investing.com South Africa
Venrock funds trim KalVista (KALV) stake, retain 5.09M shares - stocktitan.net
KalVista Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:KALV) - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Ionis Pharmaceuticals (IONS) - theglobeandmail.com
KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period - MSN
Wall Street analysts think KalVista Pharmaceuticals (KALV) could surge 117.1%: Read this before placing a bet - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 12-Month High Following Analyst Upgrade - marketbeat.com
KalVista Pharmaceuticals (KALV) Q4 Revenue Jump Tests Bullish Profitability Narrative - simplywall.st
H.C. Wainwright reiterates Kalvista stock Buy rating at $37 target By Investing.com - Investing.com Australia
Analysts Are Bullish on Top Healthcare Stocks: KalVista Pharmaceuticals (KALV), Achieve Life Sciences (ACHV) - theglobeandmail.com
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 8.7% on Analyst Upgrade - marketbeat.com
H.C. Wainwright reiterates Kalvista stock Buy rating at $37 target - Investing.com UK
KalVista Pharmaceuticals Inc Stock Baskets | HAM:4XC1 - gurufocus.com
Citizens cuts Kalvista Pharmaceuticals stock price target on steady launch By Investing.com - Investing.com Australia
KALV: Stifel Raises Price Target to $42 and Maintains Buy Rating - GuruFocus
KalVista Pharmaceuticals (NASDAQ:KALV) Given New $42.00 Price Target at Stifel Nicolaus - MarketBeat
Citizens Jmp Has Lowered Expectations for KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price - marketbeat.com
KalVista Pharmaceuticals (KALV) Target Price Lowered by Citizens Analyst | KALV Stock News - GuruFocus
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Q1 2025 Earnings Call Transcript - insidermonkey.com
Needham & Company LLC Forecasts Strong Price Appreciation for KalVista Pharmaceuticals (NASDAQ:KALV) Stock - marketbeat.com
KalVista Pharmaceuticals, Inc. Q1 2025 Earnings Call Summary - Yahoo Finance
Citizens cuts Kalvista Pharmaceuticals stock price target on steady launch - Investing.com UK
KalVista Pharmaceuticals: Global Leader in Oral Therapies for Rare Diseases and HAE Treatment Expansion 42 - Minichart
Kalvista stock price target raised to $42 by Stifel on Ekterly demand - Investing.com Australia
KalVista reports $49.1M in EKTERLY sales for eight months By Investing.com - Investing.com India
Jefferies reiterates Kalvista stock rating on strong Ekterly sales By Investing.com - Investing.com Canada
Kalvista Pharmaceuticals Inc Azioni (KALV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):